BioSpace News Archive

Can-Fite BioPharma Ltd. today announced an update on the status of its oncological lead drug candidate, Namodenoson in the treatment of advanced liver cancer.

STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference.

Harrow is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED).

Adicet Bio, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.

Precision BioSciences, Inc. today announced that the company will present preclinical data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL), highlighting the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits.

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference.

Axsome Therapeutics, Inc. today announced that it has entered into a settlement agreement with Unichem Laboratories Ltd. (Unichem) resolving patent litigation related to Axsome’s product Sunosi ® (solriamfetol).

Allurion Technologies, Inc. today announced the appointment of Ojas A. Buch as its new Chief Operating Officer.

Equillium, Inc. today announced that on May 31, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.

Boston Pharmaceuticals today announced new Phase 2a data demonstrating the positive impact of BOS-580, an investigational, long-acting fibroblast growth factor 21 (FGF21) analogue, on the circulating lipidome and changes in the metabolomics advanced steatohepatitis fibrosis (MASEF) score in patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH).